Disclosure of Interests definition

Disclosure of Interests. Xxxxxxxx Xxxx: None declared, Xxxxx Xxxxxxxxx Xxxxxxx: None declared, Xxxx Xxxxxx Xxxx: None declared, Xxxxx Xxxxxx: None declared, Xxxx Xxxxxxx Speakers bureau: Novartis, Pfizer, UCB, Xxxxxxx and GE DOI: 10.1136/annrheumdis-2022-eular.2713 AB0510 IMMUNOPHENOTYPIC RECLASSIFICATION OF XXX ASSOCIATED AUTOIMMUNE DISEASE: PRELIMINARY ANALYSIS OF FLOW CYTOMETRIC DATA IN A MULTI- DISEASE COHORT. X. Xxxxxx0,2, X. X. Xxxxxx0,2, M. Y. MD Yusof1,2, Z. Wigston1,2, S. U. Hassan1,2, X. Xxxxxx0,2, X. Xxxx0,2, X. Xxxxxxx0,2, X. Xxxxx0,2. 1University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; 2Leeds Teaching Hospitals NHS Trust, NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Disclosure of Interests. You fully understand that the Bank plays a variety of roles in connection with the Structured Investment including acting as Calculation Agent and hedging its obligations under this Structured Investment. The Bank and/or any of its related companies, in the ordinary course of their business, may also effect transactions for their own account or for the account of their customers. In conducting such business neither the Bank nor any of its related companies is obliged to take into account your circumstances or act in a manner which is favourable to you. You fully understand that such activity may, or may not affect the value of the Structured Investment and you are aware that a conflict may arise
Disclosure of Interests. Xxxx Xxxxxxx Floeistrup Xxxxxxx: None declared, Xxxxx Xxxxxxxxx Xxxxxxx: None declared, Xxxx Xxxxxxx Xxxxxxxxxx: None declared, Xxxx Xxxxx: None declared, Xxxxx Xxxxxx: None declared, Xxxxxx Xxxxxxxx: None declared, Xxxxx Møllenbach Xxxxxx: None declared, Mikkel Ǿstergaard Grant/research support from: Xxxxxx, Xxxxxxx, Cento- cor, Merck, Novartis, Consultant for: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Xxx Xxxxx, Hospira, Xxxxxxx, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB, Speakers bureau: Abbvie, BMS, Xxxx- xxxxxx-Ingelheim, Celgene, Xxx Xxxxx, Hospira, Xxxxxxx, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB DOI: 10.1136/annrheumdis-2019-eular.1951 1Croydon Health Services NHS Trust, Rheumatology, Croydon, United Kingdom; 2St George’s University Hospital NHS Trust, Rheumatology, Tooting, United Kingdom; 3Epsom and St Helier’s NHS Trust, Rheumatology, Carshalton, United Kingdom; 4King’s College Hospital NHS Foundation Trust, Rheumatology, Orpington, United Kingdom Background: To ensure a timely diagnosis of RA, diagnostic US is increasingly being utilized to detect subclinical pathology in order to implement treatment plans rapidly. There are several ‘optimal’ synovitis scoring protocols in the literature but a consensus regarding a definitive system still eludes us. There are few studies that have focussed specifi- cally on wrist US pathology in early RA. Hence, we assessed what the common wrist US pathologies are in patients diagnosed with early RA. Objectives: To identify the patterns of wrist US abnormalities seen in patients diagnosed with early RA from our EIA service in a large urban London hospital. Methods: Retrospective service review of patients seen in the EIA US diagnostic service at Croydon Health Services in South London. Patients diagnosed with RA (EULAR/ACR 2010 criteria) with wrist US synovitis/ tenosynovitis (EULAR-OMERACT definitions) between Jan2017-Dec2018 were included. The US protocol in the EIA diagnostic service includes lateral and dorsal (long axis & short axis views) of the ulnarcarpal(UCJ) & radiocarpal(RCJ) joints with views covering the radioulnar joints & ulnar-styloids and views of the extensor & flexor tendons. Images and reports were reviewed and correlations with rheumatoid factor(RhF), anti- CCP antibodies(CCP), CRP & ESR were also assessed.

Examples of Disclosure of Interests in a sentence

  • For further instructions and guidance on how to complete this notification form, please refer to section 6 of the User Guide on Electronic Notification Forms which can be accessed at the Authority’s Internet website athttp://www.mas.gov.sg (under “Regulations and Financial Stability”, "Regulations, Guidance and Licensing", "Securities, Futures and Fund Management", "Forms", "Disclosure of Interests").

  • For further instructions and guidance on how to complete this notification form, please refer to section 7 of the User Guide on Electronic Notification Forms which can be accessed at the Authority's Internet website athttp://www.mas.gov.sg (under "Regulations and Financial Stability", "Regulations, Guidance and Licensing", "Securities, Futures and Fund Management", "Forms", "Disclosure of Interests").

  • They include amendments to HKFRS 12, Disclosure of Interests in Other Entities, to clarify that the disclosure requirements of HKFRS 12, other than the requirements to disclose summarised financial information, also apply to an entity’s interests in other entities classified as held for sale or discontinued operations in accordance with HKFRS 5, Non-Current Assets Held for Sale and Discontinued Operations.

  • For further instructions and guidance on how to complete this notification form, please refer to section 9 of the User Guide on Electronic Notification Forms which can be accessed at the Authority's Internet website athttp://www.mas.gov.sg (under "Regulations and Financial Stability", "Regulations, Guidance and Licensing", "Securities, Futures and Fund Management", "Forms", "Disclosure of Interests").

  • Disclosure of Interests All Council Officers involved in the development and advice provided in this Report affirm that no direct or indirect interests need to be declared in relation to any matters in this Report.

  • IFRS 12, Disclosure of Interests in Other Entities, establishes disclosure requirements for interests in other entities, such as subsidiaries, joint arrangements, associates, and unconsolidated structured entities.

  • Data used for the freefloat adjustment are taken from publicly available sources, including financial reports, IPO prospectuses, company announcements, the Disclosure of Interests Notification History Reports from the Hong Kong Stock Exchange, FactSet and / or other research databases.

  • Aortic elasticity and the influence of valve morphology in children with bicuspid aortic valve.

  • IFRS 12 – Disclosure of Interests in Other Entities IFRS 12 establishes disclosure requirements for interests in other entities, such as joint arrangements, associates, special purpose vehicles and off balance sheet vehicles.

  • IFRS 12 Disclosure of Interests in Other Entities was released in May 2011 and is effective for annual periods beginning on or after January 1, 2013, with early adoption permitted.


More Definitions of Disclosure of Interests

Disclosure of Interests. None Declared. DOI: 10.1136/annrheumdis-2023-eular.2190 POS0920 QUANTIFICATION OF TENOSYNOVITIS IN RA FROM WRIST MRIS, BASED ON DEEP LEARNING Keywords: Artificial intelligence, Rheumatoid arthritis, Imaging
Disclosure of Interests. None Declared. DOI: 10.1136/annrheumdis-2023-eular.4372 AB0209 VALIDATION OF REVISED 2022 ACR/EULAR REMISSION CRITERIA FOR RHEUMATOID ARTHRITIS IN ASIAN INDIAN RHEUMATOID ARTHRITIS PATIENTS Keywords: Outcome measures, Rheumatoid arthritis C. B. Prasad1, V. Dhir1, G. Naidu1, S. K. Sharma1, A. Sharma1, S. Jain1. 1Post Graduate Institute of Medical Education and Research, Clinical Immunology and Rheumatology Unit, Department of Internal Medicine, Chandigarh, India Background: Remission has become a key target in the management of rheu- matoid arthritis (RA) patients[1]. In 2022, American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) has revised the Boolean based remission criteria in RA by increasing the patient global assess- ment of disease activity (PtGA) threshold to ≤2cm (range 0–10 cm). This has not been validated in an Asian Indian cohort of RA patients[2,3]. based criteria was compared. The proposed PtGA threshold of 2 cm (Boolean2.0) (range 0–10 cm) was compared with the original threshold of 1 cm (Boolean1.0) as well as with 1.5 cm, 2.5 cm and no PtGA (Boolean X) for remission. Agreement (Xxxxx’x kappa) was assessed between Boolean-based and index-based criteria. #Trial registration number: CTRI/2021/02/031361. Results: This study included 125 patients, majority being females (105 (84%)), with mean (±SD) age of 42.8 (±10.8) years and mean (±SD) disease duration of 2 (±1.5) years. At 24-weeks, using the index based (SDAI and CDAI) xxxxx- ria, remission was achieved in 24.8% and 24% of patients respectively. Among the various Boolean criteria, remission occurred in only 21.6% using the original Boolean1.0. This increased with Boolean2.0 to 23.2%, and further increased with Boolean2.5 and Boolean X [Figure 1]. The highest agreement between SDAI or CDAI-defined remission was found to occur with Boolean2.0-defined remission rather than Boolean1.0 (or 1.5, 2.5 or X) defined remission [Table 1]. Also, there was strong agreement (0.89 (95% CI 0.79-0.99)) between SDAI and CDAI-de- fined remission criteria. Conclusion: We validated the performance of revised 2022 ACR/XXXXX xxxxx- sion criteria for RA in Asian Indian RA patients and found the higher agreement of Boolean2.0 (rather than Boolean1.0) with index-based remission cutoffs.
Disclosure of Interests. None Declared. DOI: 10.1136/annrheumdis-2023-eular.4419 AB0210 CAN RHEUMATOID ARTHRITIS IMPACT OF DISEASE (RAID) SCORE BE USED AS A PATIENT REPORTED OUTCOME BASED TARGET IN A TREAT-TO-TARGET APPROACH: A PROSPECTIVE STUDY FROM INDIA Keywords: Patient reported outcomes, Rheumatoid arthritis, Treat to target P. S Kumar1, X. Xxxxx P H1, M. K. Garg1, M. Gopalakrishnan1. 1All India Institute of Medical Sciences, Internal Medicine, Jodhpur, India Background: Rheumatoid arthritis impact of disease (RAID) is a well validated patient reported outcome (PRO) in patients with Rheumatoid Arthritis (RA) [1]. RAID score involves the active participation of patients and can be easily cal- culated at the comfort of home with minimal training and assistance or while the patient is waiting to see the doctor in the outpatient department. It is helpful in giving an idea of the overall well-being of the patient and takes into account sleep and depression which are the unmet needs in RA treatment. However, the effectiveness of RAID as a patient reported outcome and the optimal RAID score which can be used as a target for treat-to-target approach has not been studied in the Indian population. Objectives: To determine if the RAID score can be used as a PRO target along with a clinician reported disease activity score for managing patients with RA under a treat-to-target approach. To establish an acceptable cut-off for the RAID score which can be used as a target in patients with RA and validate it against disease activity indices.
Disclosure of Interests. None Declared. DOI: 10.1136/annrheumdis-2023-eular.4473 AB0211 ASSESSMENT OF STIGMATIZATION IN RHEUMATOID ARTHRITIS USING THE STIGMA SCALE FOR CHRONIC ILLNESSES-SHORT FORM (SSCI-8) Keywords: Rheumatoid arthritis, Cognitive function, Mental health L. Rouached1, E. Hannech2, S. Bouden1, A. Ben Tekaya1, R. Tekaya1, I. Mahmoud1, O. Saidane1, L. Abdelmoula1. 1Charles Xxxxxxx Hospital, Rheumatology Department,Tunis,Tunisia; 1Charles Xxxxxxx Hospital, Rheumatology Department,Tunis,Tunisia Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease that occurs among productive patients. It often causes functional disability that can be permanent, with both physical and mental impact. Objectives: We aimed to assess the degree of stigmatization and associated factors in patients with RA.
Disclosure of Interests. None Declared. DOI: 10.1136/annrheumdis-2023-eular.5508 AB0212 FUNCTION AND PAIN IN KNEE JOINTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER TOTAL KNEE ARTHROPLASTY Keywords: Osteoarthritis, Rheumatoid arthritis M. Karimov1, S. Lapshina2, T. Nuriakhmetova2, I. Gilmutdinov3,

Related to Disclosure of Interests

  • Restricting Information has the meaning specified in Section 10.09(a).

  • Disclosures means the disclosures set out in ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ .

  • Disclosure shall have the meaning given to such term under the HIPAA regulations in 45 CFR § 160.103.

  • Disclosed means fairly disclosed (with sufficient details to identify the nature and scope of the matter disclosed) in or under the Disclosure Letter or the Supplementary Disclosure Letter, as appropriate;

  • Information Disclosure Requirements means the requirements to disclose information under:

  • Covered Disclosure Information shall have the meaning set forth in Section 9.2(b) hereof.

  • Confidential commercial or financial information means any business information (other than trade secrets) which is exempt from the mandatory disclosure requirement of the Freedom of Information Act, 5 U.S.C. 552. Exemptions from mandatory disclosure which may be applicable to business information contained in proposals include exemption (4), which covers “commercial and financial information obtained from a person and privileged or confidential,” and exemption (9), which covers “geological and geophysical information, including maps, concerning wells.”

  • Highly Confidential Information means Proprietary Information that is marked “Highly Confidential Information” when disclosed in written form or is otherwise designated as such hereunder.

  • Trade Secret Information means all information, regardless of the form or medium in which it is or was created, stored, reflected or preserved, that is not commonly known by or generally available to the public and that: (i) derives or creates economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use; and (ii) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. The Company’s Trade Secret Information may include, but is not limited to, all confidential information relating to or reflecting the Company’s research and development plans and activities; compilations of data; product plans; sales, marketing and business plans and strategies; pricing, price lists, pricing methodologies and profit margins; current and planned incentive, recognition and rewards programs and services; personnel; inventions, concepts, ideas, designs and formulae; current, past and prospective customer lists; current, past and anticipated customer needs, preferences and requirements; market studies; computer software and programs (including object code and source code); and computer and database technologies, systems, structures and architectures. You understand that Confidential Information and/or Trade Secret Information may or may not be labeled as such, and you shall treat all information that appears to be Confidential Information and/or Trade Secret Information as confidential unless otherwise informed or authorized by the Company. Nothing in this Agreement shall be construed to mean that Company owns any intellectual property or ideas that were conceived by you before you commenced employment with Company and which you have previously disclosed to the Company. Subject to Section 4.3(b), nothing in this Section 4.3(a) shall prevent you from complying with a valid legal requirement (whether by oral questions, interrogatories, requests for information or documents, subpoena, civil investigative demand or similar process) to disclose any Confidential Information or Trade Secret Information.

  • Disclosure Order has the meaning set forth in Section 10.7.

  • Restricted Information means any information which is disclosed to one party to this Agreement by the other pursuant to or in connection with this Agreement (whether orally or in writing, and whether or not such information is expressly stated to be confidential or marked as such);

  • Disclosed Information means the information disclosed by a Party for the purpose of settlement, negotiation, Mediation or Arbitration;

  • Highly restricted personal information means an individual’s photograph or image, social security number, digitized signature, and medical and disability information.

  • Publicly owned treatment works or “POTW” means any device or system used in the treatment (including recycling and reclamation) of municipal sewage or industrial wastes of a liquid nature which is owned by a “State” or “municipality” (as defined by section 502(4) of the CWA). This definition includes sewers, pipes, or other conveyances only if they convey wastewater to a POTW providing treatment.

  • Disclosed Matters means the actions, suits and proceedings and the environmental matters disclosed in Schedule 3.06.

  • Adverse Disclosure means any public disclosure of material non-public information, which disclosure, in the good faith judgment of the Chief Executive Officer or principal financial officer of the Company, after consultation with counsel to the Company, (i) would be required to be made in any Registration Statement or Prospectus in order for the applicable Registration Statement or Prospectus not to contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements contained therein (in the case of any prospectus and any preliminary prospectus, in the light of the circumstances under which they were made) not misleading, (ii) would not be required to be made at such time if the Registration Statement were not being filed, and (iii) the Company has a bona fide business purpose for not making such information public.

  • Publicly Owned Treatment Works (POTW means a treatment works as defined by § 212 of the CWA, which is owned by a state or municipality (as defined by § 502(4) of the CWA). This definition includes any devices and systems used in the storage, treatment, recycling, and reclamation of municipal sewage or industrial wastes of a liquid nature. It also includes sewers, pipes, and other conveyances only if they convey wastewater to a POTW treatment plant. The term also means the municipality as defined in § 502(4) of the CWA, which has jurisdiction over the indirect discharges to and the discharges from such a treatment works.

  • SEC Filings has the meaning set forth in Section 4.6.

  • Detrimental Conduct means, as determined by the Company, the Participant’s serious misconduct or unethical behavior, including any of the following: (a) any violation by the Participant of a restrictive covenant agreement that the Participant has entered into with the Company or an Affiliate (covering, for example, confidentiality, non-competition, non-solicitation, non-disparagement, etc.); (b) any conduct by the Participant that could result in the Participant’s Separation from Service for Cause; (c) the commission of a criminal act by the Participant, whether or not performed in the workplace, that subjects, or if generally known would subject, the Company or an Affiliate to public ridicule or embarrassment, or other improper or intentional conduct by the Participant causing reputational harm to the Company, an Affiliate, or a client or former client of the Company or an Affiliate; (d) the Participant’s breach of a fiduciary duty owed to the Company or an Affiliate or a client or former client of the Company or an Affiliate; (e) the Participant’s intentional violation, or grossly negligent disregard, of the Company’s or an Affiliate’s policies, rules, or procedures; or (f) the Participant taking or maintaining trading positions that result in a need to restate financial results in a subsequent reporting period or that result in a significant financial loss to the Company or an Affiliate.

  • Restrictive Agreements as defined in subsection 3.3(a).

  • Public Disclosure Documents means, collectively, all of the documents which have been filed by or on behalf of the Purchaser in the 24 months prior to the date hereof with the relevant Securities Regulators pursuant to the requirements of Securities Laws and filed on SEDAR at xxx.xxxxx.xxx;

  • Required disclosure means disclosure by the director who has a conflicting interest of:

  • voting information means postal voting information and/or e-voting information 1.2 Other expressions used in these rules and in Schedule 7 to the NHS Act 2006 have the same meaning in these rules as in that Schedule.

  • Disclosure Information As defined in the Pooling and Servicing Agreement.

  • Restricted Persons shall have the meaning assigned to such term in Section 6.9(i).

  • Restricted Parties has the meaning set forth in Section 6.15(a).